Royal Fund Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-423
| Closed | -$205K | – | 337 |
|
|
2025
Q3 | $205K | Buy |
+423
| New | +$197K | 0.02% | 229 |
|
|
2025
Q2 | – | Sell |
-4,951
| Closed | -$2.46M | – | 365 |
|
|
2025
Q1 | $2.46M | Buy |
4,951
+121
| +3% | +$65.5K | 0.27% | 122 |
|
|
2024
Q4 | $2.51M | Sell |
4,830
-4,210
| -47% | -$2.31M | 0.23% | 122 |
|
|
2024
Q3 | $5.59M | Buy |
9,040
+4,782
| +112% | +$2.83M | 0.33% | 79 |
|
|
2024
Q2 | $2.35M | Buy |
4,258
+280
| +7% | +$160K | 0.19% | 114 |
|
|
2024
Q1 | $2.31M | Buy |
3,978
+240
| +6% | +$135K | 0.23% | 130 |
|
|
2023
Q4 | $1.98M | Buy |
3,738
+395
| +12% | +$191K | 0.22% | 130 |
|
|
2023
Q3 | $1.69M | Buy |
3,343
+147
| +5% | +$78.3K | 0.23% | 120 |
|
|
2023
Q2 | $1.67M | Buy |
3,196
+142
| +5% | +$76.6K | 0.21% | 125 |
|
|
2023
Q1 | $1.76M | Buy |
3,054
+5
| +0.2% | +$2.82K | 0.25% | 107 |
|
|
2022
Q4 | $1.68M | Buy |
3,049
+51
| +2% | +$27K | 0.27% | 101 |
|
|
2022
Q3 | $1.52M | Sell |
2,998
-67
| -2% | -$37.5K | 0.28% | 104 |
|
|
2022
Q2 | $1.67M | Sell |
3,065
-112
| -4% | -$61.6K | 0.28% | 101 |
|
|
2022
Q1 | $1.88M | Buy |
3,177
+6
| +0.2% | +$3.45K | 0.27% | 96 |
|
|
2021
Q4 | $2.12M | Buy |
3,171
+216
| +7% | +$135K | 0.3% | 98 |
|
|
2021
Q3 | $1.69M | Buy |
2,955
+298
| +11% | +$164K | 0.25% | 105 |
|
|
2021
Q2 | $1.34M | Buy |
2,657
+369
| +16% | +$174K | 0.22% | 106 |
|
|
2021
Q1 | $1.04M | Buy |
2,288
+504
| +28% | +$241K | 0.19% | 108 |
|
|
2020
Q4 | $830K | Buy |
1,784
+359
| +25% | +$168K | 0.18% | 102 |
|
|
2020
Q3 | $629K | Buy |
1,425
+129
| +10% | +$53.3K | 0.16% | 104 |
|
|
2020
Q2 | $469K | Buy |
1,296
+140
| +12% | +$46.9K | 0.17% | 107 |
|
|
2020
Q1 | $327K | Buy |
1,156
+404
| +54% | +$127K | 0.13% | 94 |
|
|
2019
Q4 | $244K | Buy |
752
+137
| +22% | +$41.5K | 0.06% | 126 |
|
|
2019
Q3 | $179K | Buy |
615
+118
| +24% | +$33.8K | 0.05% | 144 |
|
|
2019
Q2 | $145K | Buy |
497
+284
| +133% | +$78.2K | 0.04% | 155 |
|
|
2019
Q1 | $58K | Hold |
213
| – | – | 0.02% | 198 |
|
|
2018
Q4 | $47K | Hold |
213
| – | – | 0.02% | 187 |
|
|
2018
Q3 | $51K | Sell |
213
-13
| -6% | -$2.99K | 0.02% | 188 |
|
|
2018
Q2 | $46K | Buy |
226
+7
| +3% | +$1.49K | 0.02% | 201 |
|
|
2018
Q1 | $45K | Buy |
219
+6
| +3% | +$1.26K | 0.02% | 201 |
|
|
2017
Q4 | $40K | Buy |
213
+13
| +7% | +$2.49K | 0.01% | 224 |
|
|
2017
Q3 | $37K | Hold |
200
| – | – | 0.01% | 198 |
|
|
2017
Q2 | $34K | Hold |
200
| – | – | 0.01% | 184 |
|
|
2017
Q1 | $30K | Hold |
200
| – | – | 0.01% | 185 |
|
|
2016
Q4 | $28K | Buy |
+200
| New | +$29.5K | 0.02% | 180 |
|
Other funds holding TMO
JSC
Royal Fund Management's TMO Position: Q4 2025 in Review
Royal Fund Management sold out of Thermo Fisher Scientific (TMO) in Q4 2025, closing a stake of 423 shares — an estimated $205K sold.
Royal Fund Management first reported a position in TMO in Q4 2016 and held it in 35 quarters. The position peaked at $5.59M in Q3 2024. 2,701 funds tracked by Wall St. Rank hold TMO as of Q4 2025.
- Royal Fund Management reported no remaining Thermo Fisher Scientific position as of Q4 2025 after selling out during the quarter.
- Royal Fund Management sold 423 Thermo Fisher Scientific shares in Q4 2025, an estimated $205K.
- Royal Fund Management first reported a position in Thermo Fisher Scientific in Q4 2016 and held it in 35 quarters.
- Royal Fund Management's Thermo Fisher Scientific position peaked at $5.59M in Q3 2024.
- 2,701 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q4 2025.
Based on Royal Fund Management's 13F filing for Q4 2025, filed 15 Jan 2026.